July 24, 2026

FDA Approves Ophthalmic Bevacizumab

The approval establishes the first and only FDA-approved ophthalmic formulation of bevacizumab for neovascular age-related macular degeneration in the US.

MDSpire News

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

April 20, 2026

Dual-Agent Eye Drop for Presbyopia

YUVEZZI™ approved for the treatment of presbyopia, blurry close-up vision due to aging

The Ophthalmologist

March 23, 2026

FDA Approves TECNIS PureSee IOL for Cataract Surgery

First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL

The Ophthalmologist

January 04, 2026

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

Contact Lens Spectrum

December 23, 2025

FDA Accepts BLA for Veligrotug for Thyroid Eye Disease

The application has been granted Priority Review, with a Prescription Drug User Fee Act target action date of June 30, 2026.

Ophthalmology Management

December 02, 2025

FDA Approves Amneal’s Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye

Cyclosporine ophthalmic emulsion 0.05% is the generic equivalent of Restasis, a registered trademark of Allergan, an AbbVie company.

Ophthalmology Management

November 10, 2025

TVC Issues Update Following White House Announcement on Tariff Policies

The Vision Council (TVC) issued a statement following new executive actions from the White House that alter tariff policies on goods imported from China.

Optometric Management

October 31, 2025

EU Approval for OFA® Analyzer

The Ophthalmologist

October 30, 2025

Sydnexis Receives Complete Response Letter From FDA Regarding Myopia Treatment

The NDA for SYD-101 was supported by the results of the phase 3 STAR trial, which evaluated more than 800 children aged 3 to 14 at treatment initiation.

Optometric Management